Clinical trials data
Cognitive tests in dementia and Alzheimer's trials: 1,673 registered studies
Every registered dementia and Alzheimer's disease study on ClinicalTrials.gov that names a cognitive test in an outcome measure: the tests used most, how often as a primary outcome, which tests go together, how large the studies are and when they measure the outcome.
- Registered dementia and Alzheimer's disease studies name a cognitive test in an outcome
- 1,673
- Led by industry
- 405
The tests dementia and Alzheimer's trials use most
The Trail Making Test leads: 273 of the 1,673 studies name it, 16%. Next comes Verbal Fluency (248). As a primary outcome, Verbal Learning leads with 102 studies.
- 1
Trail Making Test273 studies, 83 as a primary outcome
- 2
Verbal Fluency248 studies, 95 as a primary outcome
- 3
Verbal Learning224 studies, 102 as a primary outcome
- 4
Digit Span Test181 studies, 61 as a primary outcome
- 5
Category Fluency167 studies, 50 as a primary outcome
- 6
Symbol Coding117 studies, 41 as a primary outcome
- 7
Stroop Color-Word Test116 studies, 49 as a primary outcome
- 8
Picture Naming Test104 studies, 38 as a primary outcome
- 9
Short Story Recall91 studies, 36 as a primary outcome
- 10
Selective Reminding Task76 studies, 34 as a primary outcome
- 11
Delayed Recall Module71 studies, 17 as a primary outcome
- 12
Clock Drawing Task69 studies, 28 as a primary outcome
- 13
Complex Figure Copy and Recall53 studies, 23 as a primary outcome
- 14
N-Back Task44 studies, 21 as a primary outcome
- 15
Cancellation Test42 studies, 12 as a primary outcome
- 16
Paired Associate Learning34 studies, 9 as a primary outcome
- 17
Task Switching Test31 studies, 10 as a primary outcome
- 18
Choice Reaction Time25 studies, 14 as a primary outcome
- 19
Matrix Reasoning25 studies, 8 as a primary outcome
- 20
Face-name Memory Task22 studies, 13 as a primary outcome
- 21
Go/No-Go Task20 studies, 9 as a primary outcome
- 22
Line Angle Matching16 studies, 6 as a primary outcome
- 23
Continuous Performance Test14 studies, 6 as a primary outcome
- 24
Simple Reaction Time13 studies, 7 as a primary outcome
- 25
Dimensional Change Card Sort13 studies, 6 as a primary outcome
A test as a primary outcomeOnly in secondary or other outcomes
48% of dementia and Alzheimer's disease studies name only instruments outside the library, such as clinician-administered screening scales. They count in every figure on this page and are not listed. The explorer below holds all 109 tests.
Tests used together
- Digit Span Test and Trail Making Test104 studies name both
- Trail Making Test and Verbal Fluency101 studies name both
- Trail Making Test and Verbal Learning99 studies name both
- Category Fluency and Verbal Fluency93 studies name both
- Verbal Fluency and Verbal Learning80 studies name both
- Digit Span Test and Verbal Learning79 studies name both
- Digit Span Test and Verbal Fluency76 studies name both
- Category Fluency and Trail Making Test71 studies name both
- Category Fluency and Digit Span Test65 studies name both
- Stroop Color-Word Test and Trail Making Test63 studies name both
Studies by start year
A test as a primary outcomeOnly in secondary or other outcomes
Show as a table
| Start year | Studies | A test as a primary outcome |
|---|---|---|
| 2000 | 4 | 2 |
| 2001 | 3 | 1 |
| 2002 | 4 | 2 |
| 2003 | 10 | 3 |
| 2004 | 10 | 5 |
| 2005 | 13 | 6 |
| 2006 | 14 | 6 |
| 2007 | 33 | 9 |
| 2008 | 29 | 12 |
| 2009 | 35 | 11 |
| 2010 | 45 | 14 |
| 2011 | 37 | 17 |
| 2012 | 44 | 16 |
| 2013 | 49 | 23 |
| 2014 | 56 | 19 |
| 2015 | 62 | 27 |
| 2016 | 61 | 24 |
| 2017 | 74 | 25 |
| 2018 | 87 | 38 |
| 2019 | 127 | 53 |
| 2020 | 90 | 42 |
| 2021 | 109 | 45 |
| 2022 | 121 | 48 |
| 2023 | 119 | 47 |
| 2024 | 135 | 59 |
| 2025 | 169 | 69 |
| 2026 | 118 | 34 |
Phases and sponsors
By phase
- Early phase 118 studies, 5 as a primary outcome
- Phase 172 studies, 20 as a primary outcome
- Phase 1/255 studies, 18 as a primary outcome
- Phase 2274 studies, 73 as a primary outcome
- Phase 2/328 studies, 15 as a primary outcome
- Phase 3131 studies, 24 as a primary outcome
- Phase 473 studies, 21 as a primary outcome
- Not applicable746 studies, 354 as a primary outcome
- Observational276 studies, 131 as a primary outcome
Sponsors and study types
Lead sponsor: industry 405, NIH 6, universities, hospitals and others 1,262. Interventional 1,397, observational 276.
Status, results, interventions and countries
Status
- Recruiting308 studies, 113 as a primary outcome
- Not yet recruiting113 studies, 35 as a primary outcome
- Active, not recruiting66 studies, 20 as a primary outcome
- Completed778 studies, 328 as a primary outcome
- Stopped early165 studies, 64 as a primary outcome
- Status unknown243 studies, 101 as a primary outcome
What they test
- Behavioral282 studies, 136 as a primary outcome
- Drug603 studies, 163 as a primary outcome
- Device268 studies, 124 as a primary outcome
- Dietary supplement65 studies, 26 as a primary outcome
- Procedure74 studies, 37 as a primary outcome
- Diagnostic test54 studies, 20 as a primary outcome
- Biological56 studies, 11 as a primary outcome
- Radiation12 studies, 5 as a primary outcome
- Combination product7 studies, 5 as a primary outcome
- Genetic6 studies, 4 as a primary outcome
- Other370 studies, 160 as a primary outcome
- None given129 studies, 64 as a primary outcome
Intervention types as registered. A study can list several; observational studies often list none.
Where their sites are
- United States593 studies, 232 as a primary outcome
- China186 studies, 58 as a primary outcome
- Canada163 studies, 47 as a primary outcome
- Spain147 studies, 52 as a primary outcome
- France145 studies, 44 as a primary outcome
- Italy130 studies, 50 as a primary outcome
- United Kingdom126 studies, 42 as a primary outcome
- Germany110 studies, 30 as a primary outcome
- South Korea98 studies, 22 as a primary outcome
- Australia96 studies, 22 as a primary outcome
- Japan79 studies, 21 as a primary outcome
- Taiwan74 studies, 29 as a primary outcome
72 countries in all. A study with sites in several counts in each; 122 list no site.
Reported results
Completed studies with results posted on ClinicalTrials.gov, a results paper the registry links to the study, or both.
Completed dementia and Alzheimer's disease studies: 437 of 778, 56%
Every completed study with a cognitive outcome: 3,626 of 7,953, 46%
| Results | Completed dementia and Alzheimer's disease studies | Every completed study |
|---|---|---|
| Results on ClinicalTrials.gov and a paper | 127, 16% | 776, 10% |
| Results on ClinicalTrials.gov only | 135, 17% | 1,139, 14% |
| A results paper only | 175, 22% | 1,711, 22% |
| Neither | 341, 44% | 4,327, 54% |
How many participants they enroll
- Early phase 140 median, 19 to 88
- Phase 130 median, 17 to 55
- Phase 1/233 median, 15 to 49
- Phase 290 median, 43 to 196
- Phase 2/3228 median, 59 to 434
- Phase 3543 median, 223 to 1,154
- Phase 4101 median, 50 to 200
- Not applicable60 median, 33 to 129
- Observational280 median, 100 to 1,000
Show as a table
| Phase | Studies with a size | Median | Middle half |
|---|---|---|---|
| Early phase 1 | 18 | 40 | 19 to 88 |
| Phase 1 | 70 | 30 | 17 to 55 |
| Phase 1/2 | 54 | 33 | 15 to 49 |
| Phase 2 | 267 | 90 | 43 to 196 |
| Phase 2/3 | 28 | 228 | 59 to 434 |
| Phase 3 | 131 | 543 | 223 to 1,154 |
| Phase 4 | 70 | 101 | 50 to 200 |
| Not applicable | 731 | 60 | 33 to 129 |
| Observational | 270 | 280 | 100 to 1,000 |
When the cognitive outcome is measured
Latest time point of each outcome
- Within a day179 outcomes, 102 as a primary outcome
- Up to 4 weeks241 outcomes, 94 as a primary outcome
- 1 to 3 months439 outcomes, 178 as a primary outcome
- 3 to 6 months476 outcomes, 168 as a primary outcome
- 6 to 12 months429 outcomes, 119 as a primary outcome
- 1 to 2 years265 outcomes, 73 as a primary outcome
- Over 2 years225 outcomes, 105 as a primary outcome
- No duration given126 outcomes, 70 as a primary outcome
A test as a primary outcomeOnly in secondary or other outcomes
2,254 of the 2,380 outcome measures give a duration. A single visit counts as within a day.
Median time to the primary outcome, by test
| Test | Primary outcomes | Median |
|---|---|---|
| Verbal Learning | 91 | 6 months |
| Verbal Fluency | 87 | 5 months |
| Trail Making Test | 77 | 4 months |
| Digit Span Test | 55 | 6 months |
| Stroop Color-Word Test | 47 | 9 weeks |
| Category Fluency | 45 | 6 months |
| Symbol Coding | 38 | 6 months |
| Picture Naming Test | 36 | 13 weeks |
| Short Story Recall | 36 | 12 months |
| Selective Reminding Task | 32 | 10 months |
Explore the dementia and Alzheimer's disease studies
878 studies match. 380 name a library test in a primary outcome. Median size 77 participants. Median time to the primary outcome: 5 months.
Loading 878 studies; the filters turn on when they arrive.
2026 is partly planned starts. Not shown: 1 that started before 2000 and 6 planned to start after 2026.
Show as a table
| Start year | Studies | As a primary outcome |
|---|---|---|
| 2000 | 0 | 0 |
| 2001 | 3 | 1 |
| 2002 | 1 | 1 |
| 2003 | 3 | 1 |
| 2004 | 5 | 3 |
| 2005 | 13 | 5 |
| 2006 | 6 | 5 |
| 2007 | 12 | 3 |
| 2008 | 13 | 7 |
| 2009 | 22 | 7 |
| 2010 | 29 | 12 |
| 2011 | 23 | 12 |
| 2012 | 27 | 15 |
| 2013 | 32 | 16 |
| 2014 | 26 | 14 |
| 2015 | 41 | 16 |
| 2016 | 32 | 12 |
| 2017 | 43 | 18 |
| 2018 | 46 | 21 |
| 2019 | 82 | 33 |
| 2020 | 41 | 20 |
| 2021 | 56 | 27 |
| 2022 | 66 | 29 |
| 2023 | 57 | 24 |
| 2024 | 63 | 26 |
| 2025 | 81 | 32 |
| 2026 | 48 | 18 |
Library tests named most
Largest condition groups
Phases
Participants
Lead sponsor: industry 189, NIH 4, other 685. Interventional 761, observational 117.
As a primary outcomeSecondary or other outcome
The studies, newest registration first
Each number opens the study's record on ClinicalTrials.gov.
| Study | Start | Phase | Conditions | Participants | Lead sponsor | Status | Library tests named, with the latest time point |
|---|---|---|---|---|---|---|---|
| NCT07883148 | Start2024 | PhaseNot applicable | ConditionsDementia and Alzheimer's, Mild cognitive impairment | Participants52 | Lead sponsorOther | StatusCompleted | Library tests named
|
| NCT07882251 | Start2021 | PhaseNot applicable | ConditionsDementia and Alzheimer's | Participants80 | Lead sponsorOther | StatusCompleted | Library tests named
|
| NCT07856043 | Start2026 | PhasePhase 1 | ConditionsDementia and Alzheimer's, Mild cognitive impairment, Cardiovascular disease | Participants18 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07842146 | Start2026 | PhaseNot applicable | ConditionsDementia and Alzheimer's, Mild cognitive impairment | Participants60 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07842029 | Start2025 | PhaseObservational | ConditionsDementia and Alzheimer's | Participants1,000 | Lead sponsorIndustry | StatusRecruiting | Library tests named
|
| NCT07841145 | Start2026 | PhaseNot applicable | ConditionsDementia and Alzheimer's, Aging, frailty and exercise | Participants68 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07839650 | Start2026 | PhaseNot applicable | ConditionsDementia and Alzheimer's | Participants30 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07824128 | Start2026 | PhaseNot applicable | ConditionsDementia and Alzheimer's, Mild cognitive impairment, Parkinson's disease | Participants120 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07786116 | Start2025 | PhaseNot applicable | ConditionsDementia and Alzheimer's, Mild cognitive impairment, Parkinson's disease, Sleep and sleep disorders | Participants215 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07779863 | Start2027 | PhaseNot applicable | ConditionsDementia and Alzheimer's | Participants188 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07775833 | Start2026 | PhaseNot applicable | ConditionsDementia and Alzheimer's | Participants600 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07766993 | Start2026 | PhaseNot applicable | ConditionsDementia and Alzheimer's, Mild cognitive impairment | Participants100 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07741071 | Start2026 | PhasePhase 2 | ConditionsDementia and Alzheimer's | Participants270 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07731334 | Start2026 | PhaseNot applicable | ConditionsDementia and Alzheimer's, Mild cognitive impairment | Participants384 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07730671 | Start2026 | PhaseObservational | ConditionsDementia and Alzheimer's | Participants121 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07722169 | Start2026 | PhaseNot applicable | ConditionsDementia and Alzheimer's | Participants48 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07717411 | Start2026 | PhasePhase 3 | ConditionsDementia and Alzheimer's | Participants1,600 | Lead sponsorIndustry | StatusRecruiting | Library tests named
|
| NCT07700615 | Start2025 | PhasePhase 4 | ConditionsDementia and Alzheimer's | Participants120 | Lead sponsorIndustry | StatusCompleted | Library tests named
|
| NCT07692542 | Start2026 | PhaseNot applicable | ConditionsDementia and Alzheimer's | Participants40 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07673770 | Start2026 | PhaseNot applicable | ConditionsDementia and Alzheimer's | Participants30 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07672977 | Start2025 | PhaseNot applicable | ConditionsDementia and Alzheimer's, Mild cognitive impairment | Participants30 | Lead sponsorIndustry | StatusRecruiting | Library tests named
|
| NCT07667478 | Start2026 | PhaseNot applicable | ConditionsDementia and Alzheimer's, Mild cognitive impairment | Participants40 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07664865 | Start2024 | PhaseObservational | ConditionsDementia and Alzheimer's | Participants250 | Lead sponsorOther | StatusCompleted | Library tests named
|
| NCT07651787 | Start2025 | PhaseNot applicable | ConditionsDementia and Alzheimer's, Mild cognitive impairment | Participants40 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07651085 | Start2024 | PhaseObservational | ConditionsDementia and Alzheimer's, Mild cognitive impairment, Parkinson's disease, Sleep and sleep disorders | Participants65 | Lead sponsorOther | StatusActive, not recruiting | Library tests named
|
Questions, answered from the data
Which cognitive test do dementia and Alzheimer's trials use most?
The Trail Making Test: 273 of the 1,673 registered studies name it in an outcome measure, 16%. Next come Verbal Fluency (248) and Verbal Learning (224).
Which cognitive test do dementia and Alzheimer's trials use most as a primary outcome?
Verbal Learning, named in a primary outcome by 102 studies. 661 of the 1,673 studies, 40%, name a cognitive test in a primary outcome.
How many participants does a phase 2 dementia and Alzheimer's trial enroll?
Half of the phase 2 dementia and Alzheimer's disease studies enroll 90 participants or fewer, and the middle half enroll 43 to 196. 267 of them give a size.
How long after the start do dementia and Alzheimer's trials measure a cognitive outcome?
Half of the primary outcomes that name a library test are measured within 5 months of the start, and the middle half from 6 weeks to 12 months. 839 primary outcomes give a duration.
Which cognitive tests do dementia and Alzheimer's trials use together?
The Digit Span Test with the Trail Making Test most often: 104 studies name both. Next, the Trail Making Test with Verbal Fluency (101).
How many completed dementia and Alzheimer's trials have reported results?
437 of the 778 completed dementia and Alzheimer's disease studies, 56%, have reported results: 262 posted them on ClinicalTrials.gov, 302 have a results paper linked to the registry record, and 127 did both. The other 341 show neither. Of all completed studies with a cognitive outcome, 46% have reported results.
How the studies are counted
For each test family, the census runs ClinicalTrials.gov's own outcome search for the family's names and reads every study first posted by the day the family was counted. These studies were read on 10 November 2026. A study counts once on a page, however many tests it names. Counts for a test cover every version of the task under any of its names, so a page can count studies that used a commercial version.
The census adds two things to each record and changes nothing in it: which outcome list names the test (primary, then secondary, then other), and the condition groups, matched on the study's condition names and MeSH terms. A study can fall in several groups; one whose only condition is cognitive impairment or decline falls in “Cognitive impairment and decline”. Studies that name only instruments outside the library count in every total and share but are not listed.
A second read on 10 November 2026 added each study's overall status, whether results are posted, its intervention types, the countries of its sites and the time frame of the outcome that names each test. A time frame counts by the latest time point it names: “Baseline, 12 and 24 weeks” is 24 weeks, a single visit is within a day, and one that names no duration, such as “end of treatment”, is left out of the timings.
A third read on 10 November 2026 added the papers the registry links to each study: those its sponsor lists as reporting results, and those PubMed links to it through the study's NCT number. A study has a results paper when one of them came out in or after the month of its primary completion and PubMed does not class it as a protocol, review or comment. A paper that never gives the NCT number is not linked, so some studies counted as reporting neither did publish.
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine, which does not endorse these pages. Every study line is in the data release 2.1.0, and the explorer's own file is clinical-trials-studies.json.
Plan the cognitive outcomes of a dementia and Alzheimer's disease trial
Choose tests with a record in registered trials, and run them in a browser at every site, on the same version each visit.